Search Results - "Kiesel, Brian F."

ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation by Vendetti, Frank P, Karukonda, Pooja, Clump, David A, Teo, Troy, Lalonde, Ronald, Nugent, Katriana, Ballew, Matthew, Kiesel, Brian F, Beumer, Jan H, Sarkar, Saumendra N, Conrads, Thomas P, O'Connor, Mark J, Ferris, Robert L, Tran, Phuoc T, Delgoffe, Greg M, Bakkenist, Christopher J

“…DNA-damaging chemotherapy and radiation therapy are integrated into the treatment paradigm of the majority of cancer patients. Recently, immunotherapy that…”
Get full text

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10 by Abraham, Jame, Montero, Albert J, Jankowitz, Rachel C, Salkeni, Mohamad Adham, Beumer, Jan H, Kiesel, Brian F, Piette, Fanny, Adamson, Laura M, Nagy, Rebecca J, Lanman, Richard B, Sperinde, Jeff, Huang, Weidong, Allegra, Carmen J, Srinivasan, Ashok, Wang, Ying, Pogue-Geile, Katherine L, Lucas, Peter C, Jacobs, Samuel A

“…Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer eventually develop resistance to dual-antibody therapy with…”
Get full text

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer by Rodler, Eve T, Kurland, Brenda F, Griffin, Melissa, Gralow, Julie R, Porter, Peggy, Yeh, Rosa F, Gadi, Vijayakrishna K, Guenthoer, Jamie, Beumer, Jan H, Korde, Larissa, Strychor, Sandra, Kiesel, Brian F, Linden, Hannah M, Thompson, John A, Swisher, Elizabeth, Chai, Xiaoyu, Shepherd, Stacie, Giranda, Vincent, Specht, Jennifer M

“…Cisplatin is synergistic with vinorelbine and the PARP inhibitor veliparib, and has antineoplastic activity in triple-negative breast cancer (TNBC) and BRCA…”
Get full text

Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice by Deppas, Joshua J., Kiesel, Brian F., Guo, Jianxia, Parise, Robert A., Clump, D. Andy, D’Argenio, David Z., Bakkenist, Christopher J., Beumer, Jan H.

“…Background The Ataxia Telangiectasia and Rad3-related (ATR) protein complex is an apical initiator of DNA damage response pathways. Several ATR inhibitors…”
Get full text

Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice by Kiesel, Brian F., Guo, Jianxia, Parise, Robert A., Venkataramanan, Raman, Clump, David A., Bakkenist, Christopher J., Beumer, Jan H.

“…Purpose Ataxia telangiectasia and Rad3-related (ATR) initiates and regulates cellular responses to DNA damage, such as those caused by cancer treatments…”
Get full text

LC–MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma by Kiesel, Brian F., Parise, Robert A., Wong, Alvin, Keyvanjah, Kiana, Jacobs, Samuel, Beumer, Jan H.

“…[Display omitted] •Neratinib is an orally available TKI targeting EGRR and HER2 in clinical development.•An LC–MS/MS assay from 2 to 1000ng/mL in 0.1mL plasma…”
Get full text

Quantitation of the ataxia‐telangiectasia‐mutated and Rad3‐related inhibitor elimusertib (BAY‐1895344) in human plasma using LC–MS/MS by Kiesel, Brian F., Parise, Robert A., Krishnamurthy, Anuradha, Gore, Steven, Beumer, Jan H.

“…Ataxia‐telangiectasia‐mutated and Rad3‐related (ATR) is master regulator of the DNA‐damage response that, through multiple mechanisms, can promote cancer cell…”
Get full text

Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up by Pothuri, Bhavana, Brodsky, Allison L., Sparano, Joseph A., Blank, Stephanie V., Kim, Mimi, Hershman, Dawn L., Tiersten, Amy, Kiesel, Brian F., Beumer, Jan H., Liebes, Leonard, Muggia, Franco

“…Objective Poly(ADP-ribosyl) polymerases (PARPs) are nuclear enzymes with roles in DNA damage recognition and repair. PARP1 inhibition enhances the effects of…”
Get full text

Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies by Siddiqi, Tanya, Frankel, Paul, Beumer, Jan H., Kiesel, Brian F., Christner, Susan, Ruel, Chris, Song, Joo Y., Chen, Robert, Kelly, Kevin R., Ailawadhi, Sikander, Kaesberg, Paul, Popplewell, Leslie, Puverel, Sandrine, Piekarz, Richard, Forman, Stephen J., Newman, Edward M.

“…Alisertib, an Aurora kinase A inhibitor, was evaluated in a Phase 1 study in combination with the histone deacetylase inhibitor vorinostat, in patients with…”
Get full text

Neratinib-Plus-Cetuximab in Quadruple-WT ( KRAS, NRAS, BRAF, PIK3CA ) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study by Jacobs, Samuel A, Lee, James J, George, Thomas J, Wade, 3rd, James L, Stella, Philip J, Wang, Ding, Sama, Ashwin R, Piette, Fanny, Pogue-Geile, Katherine L, Kim, Rim S, Gavin, Patrick G, Lipchik, Corey, Feng, Huichen, Wang, Ying, Finnigan, Melanie, Kiesel, Brian F, Beumer, Jan H, Wolmark, Norman, Lucas, Peter C, Allegra, Carmen J, Srinivasan, Ashok

“…In metastatic colorectal cancer (mCRC), ( ) gene amplification is implicated in anti-EGFR therapy resistance. We sought to determine the recommended phase II…”
Get full text

Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice by Kiesel, Brian F., Deppas, Joshua J., Guo, Jianxia, Parise, Robert. A., Clump, David A., Bakkenist, Christopher J., Beumer, Jan H.

“…Purpose Ataxia Telangiectasia and Rad3-related (ATR) is a pivotal component of the DNA damage response and repair pathways that is activated in responses to…”
Get full text

In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine by Joshi, Anand, Kiesel, Brian F., Chaphekar, Nupur, Jones, Reyna, Guo, Jianxia, Kunos, Charles A., Taylor, Sarah, Chu, Edward, Venkataramanan, Raman, Beumer, Jan H.

“…Purpose To investigate the metabolic pathways of triapine in primary cultures of human hepatocytes and human hepatic subcellular fractions; to investigate…”
Get full text

A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620) by Malhotra, Monica K., Pahuja, Shalu, Kiesel, Brian F., Appleman, Leonard J., Ding, Fei, Lin, Yan, Tawbi, Hussein A., Stoller, Ronald G., Lee, James J., Belani, Chandra P., Chen, Alice P., Giranda, Vincent L., Shepherd, Stacie Peacock, Emens, Leisha A., Ivy, S. Percy, Chu, Edward, Beumer, Jan H., Puhalla, Shannon

“…Background Veliparib is a poly-ADP-ribose polymerase (PARP) inhibitor, and it has clinical activity with every 3 weeks carboplatin and paclitaxel. In breast…”
Get full text

A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies by Tan, Antoinette R., Chan, Nancy, Kiesel, Brian F., Stein, Mark N., Moss, Rebecca A., Malhotra, Jyoti, Aisner, Joseph, Shah, Mansi, Gounder, Murugesan, Lin, Hongxia, Kane, Michael P., Lin, Yong, Ji, Jiuping, Chen, Alice, Beumer, Jan H., Mehnert, Janice M.

“…Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in…”
Get full text

Quantitation of iohexol, a glomerular filtration marker, in human plasma by LC–MS/MS by Holleran, Julianne L., Parise, Robert A., Guo, Jianxia, Kiesel, Brian F., Taylor, Sarah E., Ivy, S. Percy, Chu, Edward, Beumer, Jan H.

“…•Iohexol is a widely used marker for measuring glomerular filtration rate (GFR).•Accurate GFR measurement is important in treatment decisions in oncology.•We…”
Get full text

Parent‐Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients With BRCA 1/2–Mutated Cancer or PARP‐Sensitive Tumor Types by Niu, Jing, Scheuerell, Christie, Mehrotra, Shailly, Karan, Sharon, Puhalla, Shannon, Kiesel, Brian F., Ji, Jiuping, Chu, Edward, Gopalakrishnan, Mathangi, Ivaturi, Vijay, Gobburu, Jogarao, Beumer, Jan H.

“…Veliparib (ABT‐888) is a novel oral poly‐ADP‐ribose polymerase (PARP) inhibitor that is being developed for the treatment of hematologic malignancies and solid…”
Get full text

Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial by Luu, Thehang, Frankel, Paul, Beumer, Jan H., Lim, Dean, Cristea, Mihaela, Appleman, Leonard J., Lenz, Heinz J., Gandara, David R., Kiesel, Brian F., Piekarz, Richard L., Newman, Edward M.

“…Purpose The reported maximum tolerated dose (MTD) of single-agent belinostat is 1000 mg/m 2 given days 1–5, every 21 days. Pre-clinical evidence suggests…”
Get full text

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction by Takebe, Naoko, Beumer, Jan H., Kummar, Shivaani, Kiesel, Brian F., Dowlati, Afshin, O'Sullivan Coyne, Geraldine, Piekarz, Richard, Rubinstein, Lawrence, Fogli, Laura K., Vaishampayan, Ulka, Goel, Sanjay, O'Bryant, Cindy L., El‐Rayes, Bassel F., Chung, Vincent, Lenz, Heinz‐Josef, Kim, Richard, Belani, Chandra P., Tuscano, Joseph M., Schelman, William, Moore, Nancy, Doroshow, James H., Chen, Alice P.

“…Aims The histone deacetylase inhibitor belinostat has activity in various cancers. Because belinostat is metabolized by the liver, reduced hepatic clearance…”
Get full text

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer by Manzo, Julia, Puhalla, Shannon, Pahuja, Shalu, Ding, Fei, Lin, Yan, Appleman, Leonard, Tawbi, Hussein, Stoller, Ronald, Lee, James J., Diergaarde, Brenda, Kiesel, Brian F., Yu, Jing, Tan, Antoinette R., Belani, Chandra P., Chew, Helen, Garcia, Agustin A., Morgan, Robert J., Wahner Hendrickson, Andrea E., Visscher, Daniel W., Hurley, Rachel M., Kaufmann, Scott H., Swisher, Elizabeth M., Oesterreich, Steffi, Katz, Tiffany, Ji, Jiuping, Zhang, Yiping, Parchment, Ralph E., Chen, Alice, Duan, Wenrui, Giranda, Vincent, Shepherd, Stacie P., Ivy, S. Percy, Chu, Edward, Beumer, Jan H.

“…Purpose BRCA1 or BRCA2 mutated cancers ( BRCA mut) have intrinsic sensitivity to PARP inhibitors due to deficiency in homologous recombination-mediated DNA…”
Get full text

Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias by Singh, Renu, Mehrotra, Shailly, Gopalakrishnan, Mathangi, Gojo, Ivana, Karp, Judith E., Greer, Jacqueline M., Chen, Alice, Piekarz, Richard, Kiesel, Brian F., Gobburu, Jogarao, Rudek, Michelle A., Beumer, Jan H.

“…Purpose Veliparib is an oral inhibitor of poly(ADP-ribose) polymerase enzyme. Combination of veliparib and temozolomide was well-tolerated and demonstrated…”
Get full text